Browsing by Author "Beer, M."
Now showing items 1-6 of 6
-
Article
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A hellenic co-operative oncology group study
Skarlos, Dimosthenis V.; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Gennatas, Constantinos; Beer, M.; Mylonakis, N.; Makrantonakis, P.; Klouvas, G. D.; Karpathios, S.; Linardou, H.; Konstantaras, C.; Fountzilas, George (1996)We compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 ...
-
Article
High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study
Fountzilas, George; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Makrantonakis, P.; Tsavaris, N.; Kalogera-Fountzila, Anna; Giannakakis, T.; Beer, M.; Kosmidis, Paraskevas A. (1991)Fifty-two women with advanced breast cancer were treated with 6 cycles of epirubicin. Even though the study was started with a dose schedule of 110 mg/m2 every 3 weeks, the average treatment interval was 26 days and the ...
-
Article
High‐dose epirubicin and r‐met‐hu G‐CSF (Filgrastim) in the treatment of patients with advanced breast cancer: A hellenic cooperative oncology group study
Fountzilas, George; Skarlos, Dimosthenis V.; Katsohis, C.; Pavlidis, Nicholas; Giannakakis, T.; Bafaloukos, Dimitrios; Fahantidis, E.; Klouvas, G. D.; Beer, M.; Kosmidis, Paraskevas A. (1995)The delivery of high‐dose epirubicin in patients with advanced breast cancer usually entails serious myelotoxicity and frequent treatment delays. Concurrent administration of G‐CSF probably allows the administration of ...
-
Article
Megestrol acetate in cancer patients with anorexia and weight loss a hellenic co-operative oncology group (heCOG) study
Skarlos, Dimosthenis V.; Fountzilas, George; Pavlidis, Nicholas; Beer, M.; Makrantonakis, P.; Aravantinos, Gerasimos; Pantelakos, P.; Tsavaris, N.; Karpasitis, N.; Kosmidis, Paraskevas A. (1993)Fifty-two patients with hormone-independent cancer, who complained of anorexia and of weight loss with at least 10% received megestrol acetate (MA), 480 mg daily, during 1-21 weeks. of the 41 patients treated during 4 weeks ...
-
Article
Original article: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site: A hellenic cooperative oncology group study
Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V.; Briassoulis, E. Ch; Beer, M.; Theoharis, D.; Bafaloukos, Dimitrios; Maravegias, A.; Fountzilas, George (1992)Summary: In this retrospective analysis 48 patients with metastatic undifferentiated carcinoma, adenocarcinoma and epidermoid carcimona of unknown origin were studied. The purpose of this analysis was to evaluate both the ...
-
Article
A Phase II trial of carboplatin and vindesine in patients with non-small cell lung cancer. A Hellenic Cooperative Oncology Group study
Pavlidis, Nicholas; Klouvas, G. D.; Nikolaides, C.; Karantanas, A. H.; Beer, M.; Fountzilas, George (1993)In an effort to investigate a regimen less toxic and more convenient than cisplatin combinations, 50 patients with non-small cell lung cancer (NSCLC) were treated in a Phase II study with carboplatin and vindesine. Carboplatin ...